TOLREMO therapeutics

We are proud to be at this year's Triple Meeting (ENA 2024) to present a first clinical update of the ongoing monotherapy dose escalation study of TT125-802. TT125-802 is a CBP/p300 bromodomain inhibitor with a unique platelet-sparing safety profile. It has demonstrated encouraging clinical activity in a range of solid tumors, including a confirmed and lasting response in EGFRmut NSCLC. We are commited to bringing benefit to patients both in the monotherapy setting as well as in combination with targeted cancer therapies, including EGFR and KRAS inhibitors in NSCLC.

The Scientific Program Committee and American Society of Clinical Oncology (ASCO) Leadership selected our Trials in Progress abstract for presentation in a poster session! Meet our team to discuss our ongoing clinical trial. Date and Time: Saturday, June 1, 9:00 AM - 12:00 PM Abstract Number: TPS3171 Abstract Title: A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of TT125-802 in patients with advanced solid tumors. #ASCO24 #StoppingCancerDrugResistance

Our CEO Stefanie Flückiger-Mangual sat down with Swisspreneur to share our unique journey.

Meet our CEO Stefanie Flückiger-Mangual and our CBO Jessica Corson at #BioEquity in San Sebastian!

Today we welcome Dr. Alan Sandler to our Scientific Advisory Board. Dr. Sandler was most recently Chief Medical Officer at Mirati Therapeutics (now Bristol Myers Squibb) where he made important contributions to the development of one of the first KRAS inhibitors.   TOLREMO’s lead asset TT125-802 has the potential to prevent resistance development to various targeted cancer therapies, indluding KRAS inhibitors.

"Advocating for the value of diversity and inclusion is not about the personal benefit of women. It’s about creating stronger businesses, better science, more innovation." Our CEO Stefanie Flückiger-Mangual talked to Drug Target Review about women in STEM - and how men can make a difference. Read the full interview here: https://lnkd.in/eBhvSMvb

We are presenting at this year's AACR annual meeting! Meet our team to discuss how we use transcriptional reprogramming in cancer to deliver new chemical scaffolds and place drug targets in a novel clinical disease context. Date and Time: April 9, 1:30 - 5:00 PM Abstract Number: 5891 Poster Title: An image-based phenotypic screen identified the bromodomain of CBP/p300 as new cancer drug resistance target and enabled the development of the clinical candidate TT125-802 #AACR24 #StoppingCancerDrugResistance

Today, we proudly welcome industry veterans Jeff Jonker and Mike Sherman to our Board of Directors. Read the press release here: https://lnkd.in/eY8KT-MZ

Will you be in the Bay Area during the #JPM conference? Come and meet the TOLREMO team, CEO Stefanie Flückiger-Mangual and CBO Jessica Corson, who will be in San Francisco from January 8-11.   Connect with us to discuss our lead candidate TT125-802 and our approach in leveraging transcriptional cancer drug resistance to transform the treatment landscape of solid tumors.

We are proud to have received CHF 1.5 million in grant funding from the Swiss Innovation Agency, Innosuisse, as part of their Start-up Innovation Project!   Innosuisse focuses on promoting science-based innovation that benefits both business and society through competitive funding for Swiss-based companies.   This recognition validates our differentiated approach and clinical strategy to stopping transcriptional cancer drug resistance as it emerges. Together with our recently closed Series A extension, the funding will allow us to continue on our mission to break resistance barriers in the fight against cancer!   To learn more about the funding, visit our website: https://lnkd.in/eY8KT-MZ   #swissinnovation